SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference, New York, NY Format – Fireside chat and 1x1 investor meetingsDate and Time – ...

Core Insights - AnaptysBio, Inc. will host a virtual investor event on its CD122 antagonist, ANB033, on October 14, 2025 [1][2] - The event will feature Dr. Joseph A. Murray from the Mayo Clinic and members of Anaptys management, followed by a Q&A session [2] - A live webcast of the presentation will be available on Anaptys' investor website, with a replay accessible afterward [3] About ANB033 - ANB033 is a potentially best-in-class CD122 antagonist targeting CD122, which is crucial for the maintenance and survival of certain immune cells [4] - The drug is currently in a Phase 1b trial for celiac disease, marking its initial indication [4] About AnaptysBio - AnaptysBio is focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [5] - The company's lead program, rosnilimab, has completed a Phase 2b trial for rheumatoid arthritis and is in a Phase 2 trial for ulcerative colitis [5] - Anaptys' pipeline includes ANB033 and ANB101, both in Phase 1 trials, and has successfully out-licensed multiple therapeutic antibodies [5]

Core Insights - AnaptysBio reported strong Phase 2b efficacy data for its lead program, rosnilimab, in rheumatoid arthritis, with plans to present updated data in June 2025 and initial ulcerative colitis data in Q4 2025 [2][7][8] - The company is advancing its autoimmune portfolio with multiple catalysts expected in the coming years, including ongoing Phase 1 trials for ANB033 and ANB101 [2][4][5] - AnaptysBio remains well-capitalized with a cash runway extending through the end of 2027, supported by a $75 million stock repurchase program and anticipated royalties from collaborations [2][11][12] Financial Updates - For Q1 2025, AnaptysBio reported collaboration revenue of $27.8 million, a significant increase from $7.2 million in Q1 2024, driven by royalties from Jemperli and revenue from the Vanda license agreement [11][19] - Research and development expenses rose to $41.2 million in Q1 2025 from $37.0 million in Q1 2024, primarily due to costs associated with Phase 2 trials for rosnilimab and Phase 1 trials for ANB033 and ANB101 [11][19] - The net loss for Q1 2025 was $39.3 million, or $1.28 per share, compared to a net loss of $43.9 million, or $1.64 per share, in the same period of 2024 [11][16][19] Portfolio Updates - Rosnilimab is in a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis, with positive results reported in a 424-patient Phase 2b RA trial [3][8][14] - ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, are both in Phase 1 trials, with enrollment ongoing for healthy volunteers [4][5][7] - The company has a collaboration with GSK, which includes anticipated milestone payments and royalties from the sales of Jemperli [9][12][14]